Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.87 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.87 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.87 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.87 |
| ▸ | CDK2 | P24941 | 15/20 | 0.87 |
| ▸ | CDK9 | P50750 | 15/20 | 0.87 |
| ▸ | CDK7 | P50613 | 9/20 | 0.76 |
| ▸ | CCNH | P51946 | 9/20 | 0.76 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26967531 | 0.89 | CCNK (0.81) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL24839386 | 0.86 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30687205 | 0.85 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL24839873 | 0.85 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL24839462 | 0.84 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL24839796 | 0.84 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30439768 | 0.84 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30439713 | 0.82 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL24839788 | 0.82 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL30204163 | 0.82 | CCNK (1.00) | CCNKCDK12CCNT1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |